К ВОПРОСУ О НАРУШЕНИЯХ В СИСТЕМЕ ПРОТЕИНА С С РАЗНООБРАЗНОЙ АКУШЕРСКОЙ ПАТОЛОГИЕЙ В АНАМНЕЗЕ У БЕРЕМЕННЫХ
Аннотация
Активированный протеин С (АРС), взаимодействуя с эндотелиальным рецептором протеина С (EPCR), рецепторами, активизируемыми протеазами (PAR), рецептором аполипопротина Е2 и интегринами, оказывает различные эффекты на систему гемостаза (антикоагулянтный эффект) и иммунную систему организма (цитопротекторный эффект). Значение системы протеина С лучше всего демонстрируется противотромботическими и воспалительными осложнениями, обусловленными дефицитом протеина С или нарушением его функции, которые в клинической практике проявляются в виде ишемического инсульта, воспалительных заболеваний, атеросклероза, сосудистых осложнений и акушерских проблем. Изучение и понимание биологической функции АРС позволяет осуществлять контроль над свертыванием и воспалением и найти применение препарата протеина С в качестве антикоагулянта и цитопротектора в клинической практике врача.
Список литературы
1. Alonso A., Soto I., Urgelles M.F. et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am. J. Obstet. Gynecol. 2002; 187: 1337-1342.
2. Ananth C.V., Nath C.A., Philipp C. The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C. J. Matern. Fetal. Neonatal. Med. 2010. 23 (12): 1377-83.
3. Andersson H.M., Arantes M.J., Crawley J.T. et al. Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1– like domain. Blood. 2010; 115 (23): 4878-85.
4. Barie P.S., Hydo L.J., Shou J. et al. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg. Infect. (Larchmt). 2011; 12 (6): 443-9.
5. Bergrem A., Dahm A.E., Jacobsen A.F., Mowinckel M.C. Resistance to activated protein C is a risk factor for pregnancy–related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br. J. Haematol. 2011; 154 (2): 241-7.
6. Dawood F., Farquharson R., Quenby S., Toh C.H. Acquired activated protein C resistance may be a risk factor for recurrent fetal loss. Fertil. Steril. 2003; 80 (3): 649-50.
7. Esmon C.T. Inflammation and the activated protein C anticoagulant pathway. Semin. Thromb. Hemost. 2006; 1: 49-60.
8. Gorbacheva L., Pinelis V., Ishiwata S., Strukova S. et al. Activated protein C prevents glutamate – and thrombin-induced activation of nuclear factor – kappaB in cultured hippocampal neurons. Neuroscience. 2010; 165 (4): 1138-46.
9. Gorbacheva L.R., Storozhevykh T.P., Pinelis V.G. et al. Activated protein C via PAR1 receptor regulates survival of neurons under conditions of glutamate excitotoxicity. Biochemistry (Mosc). 2008; 73 (6): 717-24. 10. Griffin J.H., Fernandez J.A., Gale A.J. et al. Activated protein C. J. Thromb. Haemost. 2007; 1: 73-80.
10. Hackeng T.M., Rosing J. Protein S as cofactor for TFPI. Arterioscler. Thromb. Vasc. Biol. 2009; 29 (12): 2015-20.
11. Hussein A.S., Darwish H., Shelbayeh K. Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women. Thromb. Res. 2010; 126 (2): 78-82.
12. Ivanov P., Komsa–Penkova R., Konova E., Gecheva S. Combined thrombophilic factors among women with late recurrent spontaneous abortions. Akush. Ginekol. (Sofiia). 2011; 50 (3): 8-12.
13. Underwood J., Regan L. Genetic thrombophilic mutations among couples with recurrent miscarriage. Human Reproduction. 2006; 21 (5): 1161-1165.
14. Mille-Baker B., Rezende S.M., Simmonds R.E. et al. Deletion or replacement of the second EGF – like domain of protein S results in loss of APC cofactor activity Blood. 2003; 101 (4): 1416-8.
15. Mohamed M.A., El Moaty M.A., El Kholy A.F., Mohamed S.A. et al. Thrombophilic gene mutations in women with repeated spontaneous miscarriage. Genet. Test. Mol. Biomarkers. 2010; 14 (5): 593-7.
16. Mosnier L.O., Zlokovic B.V., Griffin J.H. The cytoprotective protein C pathway. Blood. 2007;109: 3161-3172.
17. Murakami M.T., Arni R.K. Thrombomodulin–independent activation of protein C and specificity of hemostatically active snake venom serine proteinases: crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator. J. Biol. Chem. 2005; 280 (47): 39309-15.
18. Nojima J., Iwatani Y., Ichihara K., Tsuneoka H. et all Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus. Thromb. Res. 2009; 124 (1): 127-31.
19. Nojima J., Kuratsune H., Suehisa E., Iwatani Y. et all. Acquired activated protein C resistance associated with IgG antibodies against beta2–glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin. Chem. 2005; 51 (3): 545-52.
20. Norström E., Thorelli E., Dahlbäck B. Functional haracterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002; 100 (2): 524-30.
21. Olivieri O., Friso S., Manzato F. et all. Resistance to activated protein C in healthy women taking oral contraceptives. Br. J. Haematol. 1995; 91: 465-470.
22. Procházka M., Lubuský M., Slavík L., Hrachovec P., Zielina P. et all Frequency of selected thrombophilias in women with placental abruption. Aust. N. Z. J. Obstet. Gynaecol. 2007; 47 (4): 297-301.
23. Rai R., Shlebak A., Cohen H., Backos M. et all. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Human Reproduction. 2001; 16 (5): 961-965.
24. Rey E., Kahn S.R., David M., Shrier I. Thrombophilic disorders and fetal loss: a metaanalysis. Lancet. 2003; 361: 901-908.
25. Rezaie A.R. Regulation of the protein C anticoagulant and nti-inflammatory pathways. Curr. Med. Chem. 2010; 17: 2059-2069.
26. Rosendorff A., Dorfman D.M. Activated protein c resistance and factor V Leiden: a review. Arch. Pathol. Lab. Med. 2007; 131: 866-71.
27. Saposnik B., Borgel D., Aiach M. et al. Functional properties of the sex–hormone–binding globulin (SHBG)–like domain of the anticoagulant protein S. Eur. J. Biochem. 2003; 270 (3): 545-55.
28. Sarangi P.P., Lee H.W., Kim M. Activated protein C action in inflammation. Br. J. Haematol. 2010; 148 (6): 817-33.
29. Sedano-Balb´ as S., Lyons M., Cleary B., Murray M.et all. Acquired activated protein c resistance, thrombophilia and adverse pregnancy outcomes: a study performed in an irish cohort of pregnantwomen. J. Pregnancy. 2011; 1-9.
30. Sedano–Balbás S., Lyons M., Cleary B., Murray M. et all. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women. Pregnancy Childbirth. 2010; 10 (11): 1-8.
31. Sotiriadis A., Vartholomatos G., Pavlou M. et al. Combined thrombophilic mutations in women with unexplained recurrent miscarriage. Am. J. Reprod. Immunol. 2007; 57: 133-41.
32. Strukova S.M. Role of platelets and serine proteinases in coupling of blood coagulation and inflammation. Biochemistry. 2004; 69 (10): 1067-81.
33. Tchaikovski S.N., Thomassen M.C., Costa S.D., Peeters L.L., Rosing J. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. Thromb. Haemost. 2011; 106 (5): 914-21.
34. Tran S., Dahlback B. Novel APC-cleavage sites in FVa provide insights into mechanisms of action of APC and its cofactor protein S. J. Thromb. Haemost. 2010; 8: 129-136.
35. Weiler H. Multiple receptor–mediated functions of activated protein C. Hämostaseologie. 2011; 31: 185-195.
36. Zangari M., Berno T., Zhan F. et al. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis. 2011; 22 (5): 420-3.
Рецензия
Для цитирования:
Михайлиди И.А. К ВОПРОСУ О НАРУШЕНИЯХ В СИСТЕМЕ ПРОТЕИНА С С РАЗНООБРАЗНОЙ АКУШЕРСКОЙ ПАТОЛОГИЕЙ В АНАМНЕЗЕ У БЕРЕМЕННЫХ. Акушерство, Гинекология и Репродукция. 2014;8(3):59-64.
For citation:
Mikhaylidi I.A. ON THE ISSUE OF PROTEIN C SYSTEM DISORDERS IN PREGNANT WOMEN WITH VARIOUS OBSTETRIC PATHOLOGY IN PAST HISTORY. Obstetrics, Gynecology and Reproduction. 2014;8(3):59-64. (In Russ.)
Просмотров:
435
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Послать статью по эл. почте 
